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Background: A care gap exists between the health care needs of older persons with fragility 
fractures and the therapeutic answers they receive. The Fracture Prevention Service (FPS), 
a tailored in-hospital model of care, may effectively bridge the osteoporosis care gap for hip-
fractured older persons. The purpose of this study was to evaluate the efficacy of the FPS in 
targeting persons at high risk of future fracture and to improve their adherence to treatment.
Methods: This was a prospective observational study conducted in a teaching hospital with 
traumatology and geriatric units, and had a pre-intervention and post-intervention phase. The 
records of 172 participants were evaluated in the pre-intervention phase, while data from 210 
participants were gathered in the post-intervention phase. All participants underwent telephone 
follow-up at 12 months after hospital discharge. The participants were patients aged 65 years 
admitted to the orthopedic acute ward who underwent surgical repair of a proximal femoral 
fracture. A multidisciplinary integrated model of care was established. Dedicated pathways were 
implemented in clinical practice to optimize the identification of high-risk persons, improve 
their evaluation through bone mineral density testing and blood examinations, and initiate an 
appropriate treatment for secondary prevention of falls and fragility fractures.
Results: Compared with the pre-intervention phase, more hip-fractured persons received bone 
mineral density testing (47.62% versus 14.53%, P0.0001), specific pharmacological treat-
ments (48.51% versus 17.16%, P0.0001), and an appointment for evaluation at a fall and 
fracture clinic (52.48% versus 2.37%, P0.0001) in the post-intervention phase. Independent 
of some confounders, implementation of the FPS was positively associated with recommenda-
tions for secondary fracture prevention at discharge (P0.0001) and with 1-year adherence to 
pharmacological treatment (P0.0001).
Conclusion: The FPS is an effective multidisciplinary integrated model of care to optimize 
identification of older persons at highest risk for fragility fracture, to improve their clinical 
management, and to increase adherence to prescriptions.
Keywords: osteoporosis, secondary prevention, hip fracture, fracture liaison service, model 
of care
Introduction
Osteoporotic fractures mainly occur in older persons worldwide. In Italy, 90,000 
hip fractures per year affect persons aged older than 50 years, with a growing trend 
coincident with aging of the population.1 In the USA, 90% of 350,000 hip fractures 
per year occur in persons over 65 years.2 Western countries have generally reported 
increases in hip fracture incidence through the second half of the last century. Hip 
fracture rates have stabilized over the last 2 decades, with age-adjusted decreases 
being observed in some centers.3 
A fragility fracture at the hip is devastating and is associated with increased 
morbidity, disability, and mortality.4 Epidemiological studies show an annual mortality 
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rate over 25% and incomplete recovery of pre-fracture mobil-
ity in more than 50% of survivors.5–7 Approximately 60% of 
hip-fractured patients require assistance with activities of 
daily living, and 10%–20% of these patients are admitted to 
care homes in the year following the event.8 Hip fracture is 
also a strong risk factor for future vertebral and non-vertebral 
fractures. Patients who suffer a hip fracture are two to four 
times as likely to have a further hip fracture, with 10% hav-
ing another fracture within 1 year.9 Approximately 35% of 
patients hospitalized for a fragility fracture have a higher 
risk of being readmitted, with a further fragility fracture 
within 1–2 years of the previous one.10 The economic burden 
associated with direct costs (including acute in-hospital treat-
ment, post-operative complications, rehabilitation programs 
and the use of the health services) has been estimated to 
be $20 billion in the USA and €30 billion in the European 
Union. An additional burden is attributable to indirect costs 
(including burden for family members and caregivers due 
to the onset or increased disabilities) of hip fractures that 
have been only partially evaluated and weigh heavily on 
health care systems.11,12 Although guideline-recommended 
osteoporosis treatments can dramatically reduce fracture risk 
by up to 50%, about 50% of osteoporotic women and 90% 
of men with incident fragility fracture are not treated with 
any anti-fracture medication.13–17 Further, less than 25% of 
older patients who sustain fractures receive adequate vitamin 
D supplementation.18,19
In this scenario, fracture liaison services (FLS) have been 
developed in many health systems to identify persons at high 
risk for fragility fractures and/or to encourage outpatient 
primary care physicians to initiate appropriate treatment.20–22 
Epidemiological studies shown that these services may nar-
row the care gap for patients with fragility fractures, and 
they are clinically effective and cost-effective in providing 
secondary preventive care.23 Since FLS have not been widely 
adopted, mainly due to staff and service reorganization, no 
improvement in the osteoporotic care gap has been identified 
in recent years.24,25 The Fracture Prevention Service (FPS) is a 
multidisciplinary model of care tailored to identify, assess, and 
treat in an effective and timely manner all patients who suffer 
a hip fracture and are at high risk of subsequent fracture. In 
our experience, FPS was developed by optimizing available 
resources through a structured path that includes involvement 
of general practitioners, orthopedic surgeons, and other spe-
cialists involved in the treatment of osteoporosis.
The aim of this study was to evaluate the feasibil-
ity of the FPS and to estimate the association between 
implementation of the FPS and outcome measures related 
to secondary prevention of fragility fractures, including 
bone mineral density (BMD) testing, evaluation at a fall 
and fracture clinic, drug prescription, and adherence to 
pharmacological treatment. The FPS was adapted to address 
the needs of specific patient populations and it resembles 
the model of FLS that is currently considered to be the 
most effective for management of hip-fractured persons.26 
We believe that given the importance of hip fracture to the 
Italian health system and its impact on the quality of life 
of elderly people, building an FPS as in other countries is 
a mandatory objective.
Materials and methods
study design and sample
The FPS is a multidisciplinary and collaborative team, 
including orthopedic surgeons, geriatricians, physical 
therapists, nurses, and general practitioners, which assumes 
responsibility for secondary fracture prevention. The FPS 
assures case finding, assessment, and diagnostic evalua-
tion, and encourages outpatient primary care physicians 
to initiate appropriate treatment. During the period April–
December 2011, geriatricians, as providers of a fall and 
fracture clinic, met with orthopedic surgeons, nurses, physi-
cal therapists, and primary care physicians to determine the 
needs and preferences of these groups for collaboration in 
order to assure the secondary prevention of fragility fractures. 
The fall and fracture clinic is a hospital-based outpatient 
ambulatory service provided jointly by a geriatrician and 
a physiotherapist. Teaching and training activities were 
undertaken for staff involved in the FPS to raise awareness 
concerning guidelines for the diagnosis and treatment of 
osteoporosis. A fragility fracture protocol was established, 
and written guidelines for assessment and treatment of per-
sons with a proximal hip fracture were defined for staff in 
the orthopedic and traumatology department. In detail, low 
trauma hip fracture is defined as a fracture sustained as a 
result of a fall from standing height or less and not occurring 
as a consequence of a road traffic accident. All persons aged 
65 years and older admitted with low trauma hip fracture are 
identified by the orthopedic surgeons and sent the fragility 
fracture protocol. The protocol includes BMD and blood 
testing, assessment of fracture risk, and prescription and 
monitoring of antiosteoporotic treatment. At discharge, the 
FPS team members send a letter to the general practitioner 
explaining that their patient is scheduled for a comprehensive 
fracture and falls risk assessment, including BMD evaluation 
and blood tests. The main reason for a FPS in our teaching 
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Fracture prevention to bridge osteoporosis care gap
proximal femoral fracture (n=700 in 2010) in the orthopedics 
and traumatology department.
In this study, we examined the data gathered from patients 
with proximal hip fracture admitted to the orthopedics and 
traumatology department of the teaching hospital at Perugia 
from October 2010 to March 2011 and from January to 
June 2012, respectively, before and after implementation of 
the multidisciplinary and collaborative FPS team. For the 
purposes of the study, all participants received 6-month and 
12-month telephone follow-up by two trained nurses. The 
study protocol complied with the Declaration of Helsinki 
and was approved by the ethics committee of the regional 
health care system.
Demographic, clinical, and treatment-
related characteristics
We collected demographic data and information concern-
ing the type of surgery used to treat the hip fracture, along 
with the type and site of previous fragility fractures, by 
reviewing the clinical charts of patients with proximal hip 
fracture. The type of hip fracture was classified as femoral 
neck, subtrochanteric, periprosthetic, or subtrochanteric. 
Previous fragility fracture sites were classified as hip, ver-
tebral, wrist, and other. Information was collected on instru-
mental evaluation, based on BMD testing and drug therapy 
for osteoporosis, ie, calcium ± vitamin D supplementation 
and bisphosphonates or other agents ongoing before admis-
sion and/or recommended at discharge from the orthopedic 
ward. In addition, first level blood testing for secondary 
osteoporosis, including calcium, phosphorus, and plasma 
intact parathyroid hormone were collected when evaluated 
during the hospital stay. All participants received telephone 
follow-up with the aim of obtaining information about drug 
adherence or, where appropriate reasons for suspension, 
occurrence of falls, fractures, major clinical events requiring 
hospitalization, and/or mortality. Participants’ vital status 
was determined by telephone follow-up, correspondence, 
and searches of the Regional Death Index (updated in 
December 2013).
statistical analysis
Participants’ characteristics were described according to their 
pre-intervention (group A) or post-intervention (group B) 
enrollment status. Continuous variables with a symmetric 
distribution were reported as the mean and standard devia-
tion, while those with an asymmetric distribution were sum-
marized as the median and interquartile range. Categorical 
variables were summarized as proportions and percentages. 
Statistical comparisons across groups were performed using 
the Fisher’s Exact test, t-test, or chi-square test, as appropri-
ate, and sensitivity analysis was performed using McNemar’s 
test. The significance level used for two-sided tests was 
P0.05. The probability of patients receiving a specific 
antifracture drug prescription at hospital discharge as well 
as their 1-year adherence to prescribed drugs were compared 
post-FPS versus pre-FPS using multivariate regression based 
on a generalized linear model procedure (Tables 1 and 2, 
respectively). Parsimonious models were identified using 
the stepwise selection method within “proc reg” procedures. 
All analyses were performed using SAS software version 9.3 
(SAS Institute, Cary, NC, USA).
Results
Table 3 shows the characteristics of the participants grouped 
according to their enrollment phase, ie, before (group A) or 
after (group B) activation of the FPS, and stratified accord-
ing to the time of evaluation during their hospital stay, ie, at 
hospital admission or discharge. Overall, 382 hip-fractured 
older persons were enrolled in the study, comprising 172 in 
the 6 months before (group A) and 210 in the 6 months after 
Table 1 Multivariate analysis of the association between activation 
of the Fracture Prevention service and pharmacological treatment 




Fracture unit 0.34 0.04 0.0001
Age -0.001 0.002 0.6875
Female sex 0.14 0.05 0.0044
Specific treatment at admission 0.44 0.07 0.0001
history of fracture -0.13 0.04 0.0051
Abbreviation: se, standard error.
Table 2 Multivariate analysis of the association between implem-
entation of the Fracture Prevention service and 1-year adherence 
to pharmacological treatment for secondary prevention of fragility 
fracture
One-year adherence to secondary 
prevention
β SE P-value
Fracture unit 0.19 0.03 0.0001
Age -0.001 0.002 0.4864
Female sex 0.09 0.03 0.0154
Notes: Further confounders, including history of fracture, type of fracture, 
destination at discharge, history of specific treatment, and calcium and/or vitamin D 
supplementation at hospital admission were tested and excluded from the 
parsimonious model using stepwise regression method analysis.
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(group B) activation of the FPS. The majority of participants 
were women (78.49% versus 71.90%, P=0.1400) and aged 
over 80 years (83.32±8.16 versus 83.52±7.47, P=0.8090). 
In both groups, the most prevalent proximal femoral frac-
tures were at the femoral neck (49.42% versus 42.38%, 
respectively) and subtrochanteric (45.93% versus 53.81%) 
sites. Sixty percent of hip-fractured patients underwent an 
osteosynthesis procedure (59.88% versus 64.76% in the pre-
intervention group and post-intervention group, respectively) 
and about one-third underwent a prosthetic replacement, 
ie, total arthroplasty or bipolar hip prosthesis (39.53% versus 
34.76%). Overall, one of every three patients had already 
experienced a fragility fracture, with the hip being the most 
prevalent site (53.97% versus 36.00%), followed by the 
wrist (14.29% versus 13.33%) and vertebrae (12.70% versus 
16.00%). Less than 10% of patients were on antiosteoporosis 
drug treatment (10.47% versus 7.14%, P=0.2502) and/or 
vitamin D ± calcium supplementation (11.05% versus 
5.24%, P=0.0358) at admission. Few persons (1.74% versus 
0.48%) reported having BMD testing in the years before their 
fracture. Compared with group A, participants enrolled after 
activation of the FPS (group B) had a higher probability of 
receiving recommendations for secondary prevention of 
fracture at discharge. About half of them were prescribed 
specific drug treatment (48.51% versus 17.16%, P0.0001) 
and calcium ± vitamin D supplementation (50.00% versus 
16.57%, P0.0001), and obtained indications for BMD 
testing (47.62% versus 14.53%, P0.0001) and evaluation 
of fall and fracture risk (52.48% versus 2.37%, P0.0001) 
within 3 months of discharge. Bisphosphonates were the most 
commonly prescribed drugs for secondary fracture preven-
tion at discharge. Almost all hip-fractured patients in group B 
(98.00%) received calcium and vitamin D supplementation 
at discharge compared with 66.66% of those in group A. 
Almost all the characteristics of participants discharged after 
activation of the FPS were significantly different from those 
of patients discharged before the intervention (Table 3). 
Further, activation of the FPS was associated with the pre-
scription of a complete treatment for secondary fracture pre-
vention at hospital discharge, ie, a specific drug plus calcium 
and vitamin D supplementation, independent of age, sex, 
history of fracture, and ongoing drug treatment at admission 
Table 3 Characteristics of participants enrolled before (group A) and after (group B) activation of the Fracture Prevention service 






Women, n (%) 135 (78.49) 151 (71.90) 0.1400
Age, years, mean ± sD 83.32±8.16 83.52±7.47 0.8090
Clinical characteristics 






















Previous fracture, n (%) 64 (37.21) 75 (35.71) 0.7625














Diagnostic and therapy before index fracture
BMD testing, n (%) 3 (1.74) 1 (0.48) 0.2258
Antiosteoporosis drug treatment, n (%) 18 (10.47) 15 (7.14) 0.2502
Calcium and/or vitamin D supplementation, n (%) 19 (11.05) 11 (5.24) 0.0358
Diagnostic and therapy after index fracture
BMD testing, n (%) 25 (14.53) 100 (47.62) 0.0001
Fall and fractures clinic evaluation, n (%) 4 (2.37) 106 (52.48) 0.0001
Antiosteoporosis drug treatment, n (%) 29 (17.16) 98 (48.51) 0.0001
Calcium/vitamin D supplementation, n (%) 28 (16.57) 101 (50.00) 0.0001
Note: P-value from Fisher’s exact test, t-test, or chi-square test, as appropriate. 
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Fracture prevention to bridge osteoporosis care gap
(Table 1). No interaction term between antifracture treatment 
at admission and FPS was found in the model. Table 4 shows 
1-year adherence to prescriptions given to patients at hospital 
discharge and still active in follow-up (n=116 [67.44%] of 
those enrolled in group A and n=142 [67.61%] of those 
enrolled in group B). Of note, 15.7% (n=33) and 12.7% 
(n=22) of the participants died within 1 year of follow-up, 
while 16.6% (n=35) and 19.7% (n=34) dropped out for other 
reasons from group B (post-intervention) and group A (pre-
intervention), respectively. 
Of note, 15.7% (n=33) and 12.7% (n=22) of the partici-
pants died within the 1-year follow-up, while 16.6% (n=35) 
and 19.7% (n=34) dropped out for other reasons from 
group B (post-intervention) and group A (pre-intervention), 
respectively. 
Compared with patients in group A, those enrolled after 
FPS activation (group B) had higher adherence to BMD 
testing (19.64% versus 50.43%, P0.0001), fall and fracture 
clinic evaluation (4.50% versus 64.41%, P0.0001), and 
persisted on antiosteoporosis drugs (14.04% versus 44.07%, 
P0.0001) and calcium plus vitamin D supplementation 
(8.26% versus 53.51%, P0.0001, Table 4). Independent of 
age, sex, history of fracture, and ongoing drug treatments at 
admission, activation of the FPS was positively associated 
with 1-year adherence to complete pharmacological treat-
ment, ie, an antiosteoporosis drug plus vitamin D and calcium 
supplementation, for secondary prevention of fragility 
fractures (Table 2). No interaction term was found between 
activation of the FPS and history of specific treatment.
Discussion
Activation of the FPS, a multidisciplinary integrated model 
of care for secondary prevention of fragility fractures, is an 
effective strategy for increasing the probability that older 
adults at the highest risk of a subsequent fragility fracture 
receive BMD testing, fall and fracture risk assessment, 
antifracture medications, and for improving 1-year adher-
ence to treatment. In our experience, the FPS resembles a 
coordinator-based system with an osteoporosis care man-
ager, ie, a geriatrician or orthopedic surgeon, to explain the 
need for a secondary prevention fracture program to older 
persons, their relatives, and/or general practitioner, and with 
a dedicated nurse available to contact and organize access 
to the outpatient clinic for completing the diagnostic and 
therapeutic pathway.
Several models of FLS have been developed depending 
on the setting, target population, health care providers, and 
the characteristics of specific health care systems.27,28 Direct 
comparisons among models of FLS are not feasible because 
they were developed according to a different health care sys-
tem organization depending on the countries. In fact, drawing 
conclusions on the efficacy of a given model should be done 
considering the existing resources, the actual local organiza-
tion, and the priorities of the health care system. Compared 
with previous studies, we confirmed a trend toward a higher 
success rate of coordinated systems for secondary prevention 
in hip fracture patients. Although the design of the study was 
an observational pre-/post-intervention, the rates of therapeu-
tic and diagnostic antifracture recommendations markedly 
increased at discharge and were of similar magnitude to those 
in previous randomized controlled trials29–31 and studies with 
a similar design.32,33 At hospital discharge, one in two of our 
patients received appropriate management, including BMD 
testing, fall and fracture risk evaluation, and antifracture drug 
treatment. In addition, we showed significantly increased 
adherence 1 year after the hip fracture: Fifty-two percent of 
the participants still active in follow-up attended the fall and 
fracture clinic, 43% did the BMD testing, and approximately 
40% were on specific antifracture drug treatment. We 
acknowledge that still a large proportion of participants 
Table 4 One-year adherence to recommendations prescribed at discharge among participants enrolled before (group A) and after 
(group B) implementation of the Fracture Prevention service
Group A Group B P-value
Participants contributing to baseline, n (%) 172 (100%) 210 (100%) –
One-year mortality, n (%) 22 (12.7) 33 (15.7) 0.5011
One-year dropout, n (%) 34 (19.76) 35 (16.66) 0.4332
Participants contributing to 
1-year follow-up, n (%)
116 (67.44) 142 (67.61) 0.1655
BMD testing, n (%) 24 (20.68) 62 (43.66) 0.0001
Fall and fracture clinic attendance, n (%) 6 (5.17) 78 (54.92) 0.0001
Specific antifracture drug therapy, n (%) 17 (14.65) 56 (39.43) 0.0001
Calcium plus vitamin D supplementation, n (%) 10 (8.62) 65 (45.77) 0.0001
Note: P-value from Fisher’s exact test, t-test, or chi-square test, as appropriate. 
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desire indications for antifracture drug treatments, both at 
discharge as well as 1-year after fracture. Several factors 
are involved in the processes associated with improvement 
of such outcomes; some are related to the organizational 
aspects of the multidisciplinary team, but others are due to 
a limited understanding of the deleterious consequences of 
fractures on the part of patients and their carers. Several lines 
of evidence suggest that bone-protecting treatments reduce 
adverse outcomes and the incidence of subsequent fracture 
without prior dual-energy X-ray absorptiometry scanning,15 
although there is some controversy about the need for BMD 
scanning before starting secondary prevention.
An important aspect of this study is that it describes the 
first coordinator-based program to include an integrated 
approach for fall and fracture prevention in more than one 
half of participants attending an outpatient clinic. However, 
the effects of such a fall prevention program on fracture risk 
still needs to be clarified in this study sample. Another key 
element contributing to the success of this program is that it 
promoted a high level of adherence to medications by pro-
actively monitoring patients over time. The improvement 
of 1-year drug adherence in our study is an unique finding 
that was not investigated in previous randomized trials, nor 
in observational studies with a similar design. In addition, 
our model of FPS was designed to capture, evaluate, and 
treat the highest fracture risk stratum of the population. Hip-
fractured patients are particularly difficult to bring back to 
the FPS because of mobility and frailty issues. In our study, 
the FPS was structured as a multidisciplinary path, integrat-
ing available services and specialists within the hospital, to 
whom hip-fractured patients are automatically referred at the 
time they are hospitalized. Thus, activation of an appropri-
ate secondary fracture prevention protocol would no longer 
depend exclusively on the attending physician in the surgical 
(orthopedic) department, nor the patients should be more 
committed to looking for secondary fracture prevention after 
hospital discharge. Ultimately, a key factor in maximizing the 
beneficial effects of FPS was the involvement of the primary 
care physicians who contribute to begin therapy as well as 
monitor the continuity of care. Poor adherence with medica-
tions for chronic diseases is a common problem in many 
patients, especially among older persons with inadequate 
understanding of their diseases and the detrimental impact 
on the functionality. Involvement of geriatricians in the FPS 
overcomes several issues related to choice of treatment, 
management of comorbidities such as cognitive disorders, 
depression and chronic disease, polypharmacy, patient’s life 
expectancy, and preference. Coordinated interaction of the 
different professional disciplines involved, ie, geriatrician, 
orthopedic surgeon, nurse specialist, physiatrist, and general 
practitioner, and better comprehension of the risks associated 
with subsequent fragility fractures on the part of patients and 
their cares, might have contributed to the improved adherence 
to pharmacological treatment seen in our study. The good 
compliance with antifracture treatment (more than 50% in 
1 year) may also be ascribed to a more tailored choice of 
antifracture drugs. This may be considered a good result and 
represents an important and encouraging outcome of such 
intervention. Ultimately, the communication and the com-
prehension of the issues associated with fragility fractures 
improved among the older adults and their caregivers. Possible 
reasons for the higher compliance with antifracture treatment 
after activation of the FPS might be ascribed to a more tailored 
choice of antifracture drugs and improved comprehension of 
the risks associated with subsequent fragility fractures. 
Several studies from Australia, Canada, France, Ireland, 
Spain, the Netherlands, the UK, and the USA have described 
the structure and performance of FLS protocols. The optimal 
way to organize and deliver an FLS has been the subject 
of ongoing debate among service leaders and the focus of 
several systematic reviews.20–22,27,28,34–40 The most recent 
review suggests that only type A, ie, an all-encompassing 
service where patients with fragility fracture are identified, 
assessed, and treated for osteoporosis with a fracture liaison 
coordinator being central to the service, has demonstrated 
a significant reduction on the incidence of refracture. Our 
findings are consistent with these reports.25
Availability of a centralized database and a tracking sys-
tem helps provide the appropriate diagnostic and therapeutic 
protocol. Therefore, funding the information technology area 
might ultimately be cost-saving. However, in our experience, 
competing priorities for nursing time led to suboptimal data 
entry and difficulties in patients tracking, confirming the 
importance of identifying dedicated staff. The main problems 
are not medical but logistic, and the answers to these issues 
may lie in organizational aspects. Overcoming these issues is 
a priority since the spread of systematic refracture prevention 
programs in Italy and elsewhere should be given priority.
We acknowledge that our study has some limitations. 
Our evaluation of long-term adherence to antifracture drug 
prescriptions and diagnostic recommendations is limited 
to 67% of the original sample, mainly because of the high 
mortality rate (13%–16%) and dropout rate (12%–15%) in 
the study population. The main reasons for dropout were 
change of address, unwillingness to be interviewed, dete-
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Fracture prevention to bridge osteoporosis care gap
Further, our participants with hip fracture did not undergo 
a comprehensive geriatric evaluation during their hospital 
stay in the orthopedic ward. Therefore, clinical and function-
related variables that may affect the outcomes of FPS were 
not included in the analyses. Ultimately, this is a “before and 
after” study that relies on historical controls (before and after 
the period that the FPS was in effect), and not a random-
ized controlled trial. Because this study simply observed a 
change in the number of participants that received specific 
antifracture recommendations, there is always the chance 
that the change we observed was due to some unobserved 
confounding variable or systematic bias. 
In conclusion, the FPS program improved the care of 
patients with fragility fractures and positively impacted 
the cultural communication and education of health care 
providers. By identifying and addressing the needs of older 
adults at highest risk for fragility fractures, the FPS is 
expected to have long-term health and economic benefits for 
both patients and the community. We believe that develop-
ment of the FPS is effective for narrowing the deficit of care 
that exists in the management of patients with fragility frac-
tures, and it is a priority for health care systems worldwide.
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